摘要
背景与目的:有研究表明,基质金属蛋白酶(metalloproteinases,MMPs)与肿瘤的发生发展,尤其是肿瘤细胞的侵袭和转移密切相关。本研究探讨基质金属蛋白酶MMP-2、MMP-9及其组织抑制物(tissueinhibitorofmetalloproteinases-2,TIMP-2)与卵巢癌侵袭及卵巢癌生物学行为的关系。方法:采用免疫组化S-P法对128例卵巢肿瘤组织MMP-2、MMP-9及TIMP-2蛋白表达进行检测,并用χ2检验进行统计学分析。结果:免疫组化结果表明,MMP-2、MMP-9及TIMP-2在卵巢癌组织中阳性表达率明显高于卵巢囊腺瘤(P<0.01)。MMP-2及MMP-9在卵巢癌临床分期Ⅲ-Ⅳ期病例中的阳性表达率明显高于Ⅰ-Ⅱ期者,病理学分级3级病例中的表达率明显高于1-2级者(P<0.01),有淋巴结转移病例中的表达率明显高于无淋巴结转移者(P<0.01)。而TIMP-2的阳性表达与MMP-2及MMP-9相反。结论:MMP-2、MMP-9及TIMP-2的表达与卵巢癌的临床分期、病理分级及淋巴结转移有关,MMP-2及MMP-9蛋白的高表达可作为判断卵巢癌具有转移倾向的临床参考指标。
Background & Objective: Metalloproteinase(MMPs) is considered to be associated with the development of carcinoma, especially with the invasion and metastases of cancer.This study was designed to evaluate the relationship between the expression of MMP 2, MMP 9, and TIMP 2 and biological behavior of ovarian cancer. Methods: The expression of MMP 2, MMP 9, and TIMP 2 in 128 patients with ovarian tumor was determined using immunohistochemical methods,and their relationship to many clinicopathological parameters was analyzed. Results: Immunohistochemical studies revealed a diffuse granular distribution of MMP 2,MMP 9,and TIMP 2 in the cytoplasm of the carcinoma cells. The expression of MMP 2, MMP 9, and TIMP 2 was stronger in ovarian adenocarcinoma tissue than in ovarian benign tumor tissue (P< 0.01). MMP 2 and MMP 9 levels were found to be significantly higher in grade Ⅲ Ⅳ adenocarcinoma than in gradeⅠ Ⅱ adenocarcinoma (P< 0.01). MMP 2 and MMP 9 levels were significantly higher in G3 than in G1 2 tumors. Furthermore,the expression rate of MMP 2 and MMP 9 was higher in cases with lymph node metastases thanin those with non lymph node metastasis. TIMP 2 expression was contrary to the expression of MMP 2 and MMP 9 on that three respects in ovarian carcinomas. Conclusion: The expression of MMP 2, MMP 9, and TIMP 2 correlate with tumor stage, poor differentiation, and lymphnodes metastases, which suggests that co expression of MMP 2, MMP 9, and TIMP 2 within the same tumor seem to play an important role in the progression of ovarian cancer and could be useful prognostic markers for patients with ovarian carcinoma.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
2002年第1期91-94,共4页
Chinese Journal of Cancer
